Mechanisms for industry input on FDA guidance agenda suggested in comments.
This article was originally published in The Gray Sheet
Executive Summary
GUIDANCE DOCUMENT "CALENDAR" COULD PROVIDE OPPORTUNITY FOR INDUSTRY PROPOSALS for FDA guidance documents, in addition to listing the agency's guidance development plans, Steris says in recent comments on FDA's good guidance practices proposal ("The Gray Sheet" March 11, I&W-3). The calendar "would list all planned guidance document activities, including all opportunities for written and oral comments, and would allow members of the public to propose guidance document topics," the sterilizer company suggests. FDA or an industry committee "may need to loosely filter" the proposals "to avoid an explosion of meritless calendar listings," Steris adds.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.